Matches in SemOpenAlex for { <https://semopenalex.org/work/W83046870> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W83046870 endingPage "613" @default.
- W83046870 startingPage "613" @default.
- W83046870 abstract "613 Background: TAC (docetaxel, doxorubicin and cyclophosphamide) chemotherapy has been accepted as an adjuvant chemotherapy for the node positive breast cancer. But, moderate to severe adverse reactions, especially neutropenia, right after this regimen have been major hurdle for the wider enthusiasm. Until now, ciprofloxacin has been given to patients on completion of each cycle to prevent systemic infection. We tried to determine if ciprofloxacin is to be included in the post-chemotherapy medications or not to stop possible infection. Methods: We randomly assigned 100 patients into two groups between Jan. 2006 to Oct. 2007. Study group (A; n=50 patients, 300 cycles) was given prophylactic G-CSF (300 ug) from day 5 to day 10, and the control group (B; n=50, 300 cycles) was given G-CSF and ciprofloxacin (500 mg, orally twice daily) from day 5 to 10. We compared the incidence of infection and neutropenia prospectively. This study was reviewed by the IRB and informed consent from the patient should be compulsory for her to be included in this trial. Results: The incidence of infection in group A was 0.5% and in group B was 0.4% (p=0.14). The incidence of febrile neutropenia was 12% (A) versus 10% (B) (p=0.09). We couldn't find the significant differences in grade 4 neutropenia nor leukopenia after G-CSF with/without ciprofloxacin. Conclusions: The use of ciprofloxacin was not helpful to reduce systemic infection nor neutropenia after TAC chemotherapy. Even though larger number of patients should be enrolled to get the definite answer to delineate the protective role of ciprofloxacin against infection or neutropenia, we don't think that ciprofloxacin itself gives additional advantage to the patients having TAC chemotherapy to go through all cycles with less adverse reactions. No significant financial relationships to disclose." @default.
- W83046870 created "2016-06-24" @default.
- W83046870 creator A5008493307 @default.
- W83046870 creator A5017028026 @default.
- W83046870 creator A5022105113 @default.
- W83046870 creator A5023554560 @default.
- W83046870 creator A5050636008 @default.
- W83046870 date "2008-05-20" @default.
- W83046870 modified "2023-09-25" @default.
- W83046870 title "Prevention of infection after TAC chemotherapy for node-positive breast cancer as an adjuvant therapy with or without ciprofloxacin" @default.
- W83046870 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.613" @default.
- W83046870 hasPublicationYear "2008" @default.
- W83046870 type Work @default.
- W83046870 sameAs 83046870 @default.
- W83046870 citedByCount "0" @default.
- W83046870 crossrefType "journal-article" @default.
- W83046870 hasAuthorship W83046870A5008493307 @default.
- W83046870 hasAuthorship W83046870A5017028026 @default.
- W83046870 hasAuthorship W83046870A5022105113 @default.
- W83046870 hasAuthorship W83046870A5023554560 @default.
- W83046870 hasAuthorship W83046870A5050636008 @default.
- W83046870 hasConcept C121608353 @default.
- W83046870 hasConcept C126322002 @default.
- W83046870 hasConcept C141071460 @default.
- W83046870 hasConcept C2776694085 @default.
- W83046870 hasConcept C2776755627 @default.
- W83046870 hasConcept C2777063308 @default.
- W83046870 hasConcept C2778512257 @default.
- W83046870 hasConcept C2778850193 @default.
- W83046870 hasConcept C2780873365 @default.
- W83046870 hasConcept C2781190966 @default.
- W83046870 hasConcept C2781413609 @default.
- W83046870 hasConcept C501593827 @default.
- W83046870 hasConcept C530470458 @default.
- W83046870 hasConcept C71924100 @default.
- W83046870 hasConcept C86803240 @default.
- W83046870 hasConcept C89423630 @default.
- W83046870 hasConceptScore W83046870C121608353 @default.
- W83046870 hasConceptScore W83046870C126322002 @default.
- W83046870 hasConceptScore W83046870C141071460 @default.
- W83046870 hasConceptScore W83046870C2776694085 @default.
- W83046870 hasConceptScore W83046870C2776755627 @default.
- W83046870 hasConceptScore W83046870C2777063308 @default.
- W83046870 hasConceptScore W83046870C2778512257 @default.
- W83046870 hasConceptScore W83046870C2778850193 @default.
- W83046870 hasConceptScore W83046870C2780873365 @default.
- W83046870 hasConceptScore W83046870C2781190966 @default.
- W83046870 hasConceptScore W83046870C2781413609 @default.
- W83046870 hasConceptScore W83046870C501593827 @default.
- W83046870 hasConceptScore W83046870C530470458 @default.
- W83046870 hasConceptScore W83046870C71924100 @default.
- W83046870 hasConceptScore W83046870C86803240 @default.
- W83046870 hasConceptScore W83046870C89423630 @default.
- W83046870 hasIssue "15_suppl" @default.
- W83046870 hasLocation W830468701 @default.
- W83046870 hasOpenAccess W83046870 @default.
- W83046870 hasPrimaryLocation W830468701 @default.
- W83046870 hasRelatedWork W1858470829 @default.
- W83046870 hasRelatedWork W2008532313 @default.
- W83046870 hasRelatedWork W2084414488 @default.
- W83046870 hasRelatedWork W2093981422 @default.
- W83046870 hasRelatedWork W2106964779 @default.
- W83046870 hasRelatedWork W2413468807 @default.
- W83046870 hasRelatedWork W2489364001 @default.
- W83046870 hasRelatedWork W2560682459 @default.
- W83046870 hasRelatedWork W2596514400 @default.
- W83046870 hasRelatedWork W3000675521 @default.
- W83046870 hasVolume "26" @default.
- W83046870 isParatext "false" @default.
- W83046870 isRetracted "false" @default.
- W83046870 magId "83046870" @default.
- W83046870 workType "article" @default.